Avecho Biotechnology Ltd has released a press release.
December 2021 Quarterly Activities Report & Appendix 4C
Filed with ASX ·
6ix hasn’t read this filing yet.
Avecho Biotechnology Limited on 6ix
Story so far
Earlier from Avecho Biotechnology
- Application for quotation of securities - AVE
- AVE Licenses CBD Soft-Gel to Medterra Pharma for Arthritis
- Positive results from Avechos Phase I trial of CBD soft-gel
- September 2021 Quarterly Activities Report & Appendix 4C
- Topical CBD pain study with Lambert Initiative approved
Later from Avecho Biotechnology
- AVE license agreement for US recreational cannabis market
- Appendix 4E and Annual Report 31 December 2021
- Dosing begins in topical CBD pain study
- Positive results from AVEs topical CBD pain study
- March 2022 Quarterly Activities Report & Appendix 4C
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology